This is the first gene editor to use a CRISPR-associated transposase to make targeted edits at therapeutically useful levels in humans.

10x Genomics has settled patent infringement lawsuits with a pair of rivals, Bruker and Vizgen, through settlements that could reshape competition within the emerging single-cell and spatial genomics ...

Element has responded to the lawsuit with a statement saying, “Element is proud of its strong history of innovation. We are reviewing the complaint and look forward to defending our innovations in ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.